Search PubMed⌕ Search

Biomedical subjects

M Dominguez

Publications and source records attributed to M Dominguez.

At least 73 records · Page 4Linked to original sources
PubMed1984

Resistance of Aeromonas hydrophila to beta-lactam antibiotics.

The activity of some beta-lactam antibiotics upon 20 strains of Aeromonas hydrophila and some properties of their beta-lactamases have been studied. High degree of resistance to benzylpenicillin and lower resistance to ampicillin and cephaloridine was observed. Clavulanic acid showed the highest activity. When clavulanic acid was assayed at subinhibitory concentrations in association with ampicillin. MICs of the latter decreased to two- to eight-fold. All strains produced inducible beta-lactamases with high activity upon ampicillin. A group of cephalosporinase-like enzymes was also found. Some beta-lactamases were inhibited by cloxacillin, and most of them were completely inhibited by 5 mg/l of clavulanic acid. Low impermeability of Aerom. hydrophila cells to beta-lactams was observed.

Aeromonas↗
PubMed1983

Differential susceptibility of Aeromonas hydrophila and Enterobacteriaceae to nalidixic acid.

The susceptibility of 49 strains of Aeromonas hydrophila and 77 strains of Enterobacteriaceae towards nalidixic acid was compared by tube dilution and agar diffusion methods. A higher susceptibility was exhibited by Aerom. hydrophila and no overlap in MICs was found for strains of the two groups of microorganisms. Discs containing 0.25 microgram of nalidixic acid produced measurable zones of growth inhibition with Aerom. hydrophila and no zones with the Enterobacteriaceae. The use of a disc with 0.25 microgram of nalidixic acid for the primary differentiation of strains of Aerom. hydrophila from those of the Enterobacteriaceae with similar biochemical properties is suggested.

Aeromonas↗
PubMed1978

Pathophysiological studies in idiopathic hypercalciuria: use of an oral calcium tolerance test to characterize distinctive hypercalciuric subgroups.

Twenty-one unselected patients with recurrent nephrolithiasis and normocalcemic hypercalciuria with or without hypophosphatemia and 18 normal subjects were studied with an oral calcium tolerance test and for 3- to 5-day periods while consuming a low normal (400 mg) and high-normal (1000 mg) calcium intake. The oral calcium tolerance test consisted of the measurement of the calcemic, calciuric, and parathyroid (assessed by determinations of serum immunoreactive parathyroid hormone and nephrogenous cAMP) responses to acute 1000- or 350-mg doses of calcium. Nineteen patients displayed normal results for basal serum calcium, parathyroid function, and fasting calcium excretion, and striking calcemic (mean increase in serum calcium, 0.9 vs. 0.2 mg/dl in the normal subjects) and calciuric (mean increase in urinary calcium, 0.33 vs. 0.15 mg calcium/100 ml GF in the normal subjects) responses to the 1000-mg calcium tolerance test, associated with a mean 54% suppression in nephrogenous cAMP. These patients were operationally defined as having "absorptive" hypercalciuria. The variable occurrence of hypophosphatemia in this group suggested that the pathogenesis of "absorptive" hypercalciuria may be complex and/or multifactorial. There were strong positive correlations between the calciuric response to the calcium tolerance test and fractional isotopic calcium absorption (r = 0.75, P less than 0.00), the calcemic responses to the test (r = 0.71, P less than 0.001) and the calciuric responses noted on the 1000- vs. the 400-mg daily calcium intake (r = 0.78, P less than 0.001). Two patients displayed low or low normal basal serum calcium, increased parathyroid function, increased fasting calcium excretion, and a striking calciuric but minimal calcemic response to the 1000-mg calcium tolerance test, associated with a moderate suppression in nephrogenous cAMP. These patients were operationally defined as having "renal" hypercalciuria. Several lines of evidence indicated that the hyperparathyroidism in these patients was physiological or secondary, including the near normalization of parathyroid function on the daily 1000-mg calcium intake. A steep slope of calcium excretion on calcium intake (due to increased calcium absorption) was noted in all hypercalciuric patients and accounted for the significantly improved diagnostic accuracy of screening patients for hypercalciuria on the high-normal calcium intake. The simple measurement of total cAMP excretion (nanomoles per 100 ml GF) and urinary calcium on the 1000-mg daily calcium intake seemed to provide reliable separation of patients with "renal" from those with "absorptive" hypercalciuria. A physiological (350 mg) dose of oral calcium produced a 30% suppression of nephrogenous cAMP in normal subjects; this suggests that dietary calcium exerts an important control of parathyroid function under physiological circumstances.

Adult↗
PubMedDate not supplied

Bone mineral metabolism is normal in non-insulin-dependent diabetes mellitus.

Because of the previous controversial findings in non-insulin-dependent diabetes mellitus (NIDDM), we measured bone-mineral density (BMD) by two different methods, studied biochemical markers of bone remodeling and calciotropic hormones (parathyroid hormone and calcitonin) in women with NIDDM, and compared the results with age-matched controls. Forty-seven women with NIDDM and 252 healthy nondiabetic women as controls were recruited for this study. BMD was measured by dual X-ray absorptiometry (DEXA) and by quantitative computed tomography (QCT). Biochemical markers of bone remodeling included plasma alkaline phosphatase (AP), osteocalcin (BGP), tartrate-resistant acid phosphatase (TRAP), parathyroid hormone (PTH), calcitonin (CT), and 24-h urine calcium, hydroxyproline. Diabetic patients were more obese with a higher body-mass index (BMI) than controls. Bone mass was normal in NIDDM, both by DEXA and by QCT. Biochemical markers of bone remodeling, PTH and CT were also normal. There was no statistical correlation between bone mass and any of the other measurements studied. There is no evidence that NIDDM produces any change in bone metabolism or mass.

Absorptiometry, Photon↗
PubMedDate not supplied

[Cerebral infarct in childhood as a complication of migraine with aura. A case report].

INTRODUCTION: A migrainous infarct is a complication which may occur during the course of an attack of migraine, especially during the phase of the aura. It is the cause of between 1 and 14% of the cerebral infarcts in children. Even today there is still controversy as to whether it occurs in childhood, in spite of a strongly based clinical suspicion of it, since it is difficult to prove the chain of clinicopathological events scientifically. CLINICAL CASE: We report the clinical case of an adolescent girl of eleven years of age who complained of having attacks of migraine with aura for the previous two years and fulfilled the criteria of the International Headache Society (IHS). She was referred to us when a cranial CAT scan showed a hypodense area at the level of the ganglia of the left base, although neurological examination was still normal. The probable ischaemic nature of the lesion was confirmed using neuroimaging techniques (magnetic resonance). On electroencephalography there was a slow focal pattern which was moderately persistent in the left temporal cortex. Other causes of cerebral infarct were rules out on further complementary studies. CONCLUSIONS: The patient therefore fulfilled the criteria of the IHS for diagnosis of a migrainous infarct. We also analyze the main findings regarding clinical history, epidemiology, clinical findings and diagnosis of migrainous infarct in childhood.

Brain↗
PubMedDate not supplied

[Epilepsy and pregnancy].

INTRODUCTION: Treatment of the epileptic patient during pregnancy poses a major clinical dilemma. For one thing the patient has to be kept free of seizures, but she also should be kept on monotherapy at the lowest possible dose, due to the effect such medication may have on the unborn child. DEVELOPMENT: There is a syndrome related to intra uterine exposure to the classical antiepileptic drugs, but which is not associated with any particular drug. However, the effect of the new antiepileptic drugs on unborn children is still unknown. To date, no specific pattern of malformations has been described in relation to any of these drugs. Lamotrigine is the one with which there is most clinical experience. Although there are still not enough cases studied to permit definite conclusions to be drawn, at the moment the incidence of congenital anomalies is the same as in the general population. CONCLUSIONS: The new anti-epileptic drugs have a major therapeutic advantage, not only in the management of epilepsy in different clinical situations, but also in the good results observed when using lamotrigine in patients of fertile age.

Abnormalities, Drug-Induced↗